The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Lars Hjalmar Lindholm

Department of Public Health and Clinical Medicine

Umeå University

SE 901 85

Sweden

[email]@fammed.umu.se

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Department of Public Health and Clinical Medicine, Umeå University, SE 901 85, Sweden. 2001 - 2007
  • Umeå University Hospital, Sweden. 2002 - 2006
  • Steno Diabetes Centre, Gentofte, Denmark. 2002

References

  1. Prevention of cardiovascular disease in developing countries. Lindholm, L.H., Mendis, S. Lancet (2007) [Pubmed]
  2. Cost implications of development of diabetes in the ALPINE study. Lindholm, L.H., Kartman, B., Carlberg, B., Persson, M., Svensson, A., Samuelsson, O. J. Hypertens. Suppl (2006) [Pubmed]
  3. Beta blockers in primary hypertension: Do age and type of beta-blocker matter?. Lindholm, L.H., Carlberg, B., Samuelsson, O. J. Hypertens. (2006) [Pubmed]
  4. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lindholm, L.H., Carlberg, B., Samuelsson, O. Lancet (2005) [Pubmed]
  5. Valsartan treatment of hypertension--does VALUE add value?. Lindholm, L.H. Lancet (2004) [Pubmed]
  6. What are the odds at ASCOT today?. Lindholm, L.H., Samuelsson, O. Lancet (2003) [Pubmed]
  7. Major benefits from cholesterol-lowering in patients with diabetes. Lindholm, L.H. Lancet (2003) [Pubmed]
  8. Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study. Lindholm, L.H., Dahlöf, B., Edelman, J.M., Ibsen, H., Borch-Johnsen, K., Olsen, M.H., Snapinn, S., Wachtell, K. Lancet (2003) [Pubmed]
  9. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lindholm, L.H., Ibsen, H., Dahlöf, B., Devereux, R.B., Beevers, G., de Faire, U., Fyhrquist, F., Julius, S., Kjeldsen, S.E., Kristiansson, K., Lederballe-Pedersen, O., Nieminen, M.S., Omvik, P., Oparil, S., Wedel, H., Aurup, P., Edelman, J., Snapinn, S. Lancet (2002) [Pubmed]
  10. The status of hypertension therapy. Lindholm, L.H., Moser, M. J. Hypertens. Suppl (2002) [Pubmed]
  11. The problem of uncontrolled hypertension. Lindholm, L.H. J. Hum. Hypertens (2002) [Pubmed]
  12. Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. Lindholm, L.H., Ibsen, H., Borch-Johnsen, K., Olsen, M.H., Wachtell, K., Dahlöf, B., Devereux, R.B., Beevers, G., de Faire, U., Fyhrquist, F., Julius, S., Kjeldsen, S.E., Kristianson, K., Lederballe-Pedersen, O., Nieminen, M.S., Omvik, P., Oparil, S., Wedel, H., Aurup, P., Edelman, J.M., Snapinn, S. J. Hypertens. (2002) [Pubmed]
  13. Relation between drug treatment and cancer in hypertensives in the Swedish Trial in Old Patients with Hypertension 2: a 5-year, prospective, randomised, controlled trial. Lindholm, L.H., Anderson, H., Ekbom, T., Hansson, L., Lanke, J., Dahlöf, B., de Faire, U., Forsén, K., Hedner, T., Linjer, E., Scherstén, B., Wester, P., Möller, T. Lancet (2001) [Pubmed]
 
WikiGenes - Universities